LUTREPULSE POWDER FOR SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

GONADORELIN ACETATE

Verfügbar ab:

FERRING INC

ATC-Code:

H01CA01

INN (Internationale Bezeichnung):

GONADORELIN

Dosierung:

3.2MG

Darreichungsform:

POWDER FOR SOLUTION

Zusammensetzung:

GONADORELIN ACETATE 3.2MG

Verabreichungsweg:

INTRAVENOUS

Einheiten im Paket:

10ML VIAL

Verschreibungstyp:

Prescription

Therapiebereich:

GONADOTROPINS AND ANTIGONADOTROPINS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0121867001; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2010-08-27

Fachinformation

_ _
_Pr_
_LUTREPULSE_
_®_
_ _
_Page 1 of 45 _
PRODUCT MONOGRAPH
Pr
LUTREPULSE
®
Gonadorelin Acetate for Injection
3.2 mg/vial
(0.9% Sodium Chloride for Injection (USP) (diluent)
Subcutaneous (SC) Use Only
Ovulatory Agent
Ferring Inc.
200 Yorkland Blvd.
Suite 500
North York, Ontario
M2J 5C1
Date of Revision:
May 17, 2016
Submission Control No: 187199
_ _
_Pr_
_LUTREPULSE_
_®_
_ _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
..........................................................................................................26
TOXICOLOGY
.....................................................................................